(Nasdaq:CRBP) Corbus Pharmaceuticals Holdings Inc Analysts Are

Corbus Pharmaceuticals Holdings Inc (Nasdaq:CRBP)

September 20th, 2018

Amidst rising markets Corbus Pharmaceuticals Holdings Inc closed Thursday up 53.62%, a $2.77 increase to close on $7.95. Corbus Pharmaceuticals Holdings Inc bounced 59.66% between high and low. In addition to finishing higher, trading volumes were solid at 4,217% of normal which can indicate investors see opportunities.

CRBP outperformed the rest of the Healthcare sector which went up 0.93% today.

Market Sectors

The market sectors were mixed Thursday with a majority of the sectors trending up. Information Technology saw the biggest increase of the day (1.17%), while Energy saw the biggest drop (0.06%). Consumer Discretionary has seen the biggest year-to-date gain at 18%. The biggest loss this year has been the Telecommunication Services sector dropping 5.70%.

Consumer Staples saw the biggest turnaround from its 5-day performance of -0.82%, as it went up 1.16%. Energy saw a turn around from its 5-day performance of 1.82% trading down 0.06%.

Sector Breakdown

  • Information Technology went up with a 1.17% change.
  • Consumer Staples went up with a 1.16% change.
  • Materials went up with a 1.05% change.
  • Healthcare went up with a 0.93% change.
  • Financials went up with a 0.80% change.
  • Real Estate went up with a 0.76% change.
  • Consumer Discretionary went up with a 0.66% change.
  • Telecommunication Services went up with a 0.45% change.
  • Utilities went up with a 0.12% change.
  • Industrials went up with a 0.11% change.
  • Energy went down with a -0.06% change.

Corbus Pharmaceuticals Holdings Inc Info

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. The company was founded in 2009 and is based in Norwood, Massachusetts.

All amounts in USD unless otherwise indicated

CRBP daily update
CRBP daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.